Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Encourages Pediatric Master Protocols With Bayesian Approach

Executive Summary

Most trials currently use of frequentist statistics, but agency argues that Bayesian methods allow for better extrapolation.


Related Content

Mutual Recognition's Next Evolution May Be Sharing Info On India And China Inspections
US FDA's Brexit: One Staffer Moving, But Impact Still May Loom Large
Orphan Drug Development: Could We Be Seeing The End Of P Values?
Master Protocols In Practice
Genentech Wants Other Firms' Compounds For Mass Pediatric Cancer Screening
I-SPY 2 Helping To Normalize Adaptive Trial Designs





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts